Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. More Details
Flawless balance sheet with moderate growth potential.
Share Price & News
How has Fennec Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FENC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: FENC exceeded the US Biotechs industry which returned 32.5% over the past year.
Return vs Market: FENC exceeded the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Fennec Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShould You Review Recent Insider Transactions At Fennec Pharmaceuticals Inc. (NASDAQ:FENC)?
1 month ago | Simply Wall StWe're Not Very Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn Rate
2 months ago | Simply Wall StWhat Kind Of Investors Own Most Of Fennec Pharmaceuticals Inc. (NASDAQ:FENC)?
Is Fennec Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate FENC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate FENC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FENC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: FENC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FENC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FENC is overvalued based on its PB Ratio (5.4x) compared to the US Biotechs industry average (3.4x).
How is Fennec Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FENC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: FENC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: FENC's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if FENC's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if FENC's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FENC's Return on Equity is forecast to be high in 3 years time
How has Fennec Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FENC is currently unprofitable.
Growing Profit Margin: FENC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FENC is unprofitable, and losses have increased over the past 5 years at a rate of 48.2% per year.
Accelerating Growth: Unable to compare FENC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FENC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).
Return on Equity
High ROE: FENC has a negative Return on Equity (-39%), as it is currently unprofitable.
How is Fennec Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: FENC's short term assets ($38.9M) exceed its short term liabilities ($3.2M).
Long Term Liabilities: FENC has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: FENC is debt free.
Reducing Debt: FENC has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FENC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: FENC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 36.7% each year
What is Fennec Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FENC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FENC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FENC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FENC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FENC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rosty Raykov (44 yo)
Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of Fennec Pharmaceuticals Inc. (alternate name Adherex Technologies Inc) since July 2009 and serves as its President. Mr. Ray ...
CEO Compensation Analysis
Compensation vs Market: Rosty's total compensation ($USD1.48M) is about average for companies of similar size in the US market ($USD1.23M).
Compensation vs Earnings: Rosty's compensation has increased whilst the company is unprofitable.
|CEO & Director||11.25yrs||US$1.48m||0.78% |
|Chief Financial Officer||4.92yrs||US$863.77k||0.60% |
|Chief Commercial Officer||1.08yrs||US$1.23m||0% |
|Controller||4.92yrs||no data||no data|
|President of Pharstat Inc||no data||no data||no data|
|Regulatory Consultant||10.42yrs||no data||no data|
|Consultant||no data||no data||no data|
Experienced Management: FENC's management team is considered experienced (4.9 years average tenure).
|CEO & Director||11.25yrs||US$1.48m||0.78% |
|Independent Director||9.17yrs||US$126.65k||0% |
|Independent Chairman of the Board||4.83yrs||US$190.19k||0% |
|Independent Director||1.08yrs||US$112.43k||0% |
|Independent Director||6.5yrs||US$124.15k||0% |
|Independent Director||4.17yrs||US$124.15k||0% |
Experienced Board: FENC's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: FENC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.4%.
Fennec Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Fennec Pharmaceuticals Inc.
- Ticker: FENC
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$195.495m
- Shares outstanding: 25.36m
- Website: https://www.fennecpharma.com
Number of Employees
- Fennec Pharmaceuticals Inc.
- 68 TW Alexander Drive
- PO Box 13628
- Research Triangle Park
- North Carolina
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|FRX||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Jun 2001|
|RV41||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jun 2001|
|FENC||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Jun 2001|
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 05:26|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.